Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...
On Monday, Fate Therapeutics Inc (FATE) stock saw a modest uptick, ending the day at $2.72 which represents a slight increase of $0.07 or 2.64% from the prior close of $2.65. The stock opened at $ and ...
Fate Therapeutics Inc (FATE) stock saw a decline, ending the day at $1.83 which represents a decrease of $-0.09 or -4.69% from the prior close of $1.92. The stock opened at $1.97 and touched a low of ...
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has received an average recommendation of “Hold” from the ten ratings ...
SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to ...
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...
It has been about a month since the last earnings report for Fate Therapeutics (FATE). Shares have added about 0.5% in that time frame, underperforming the S&P 500. Will the recent positive trend ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback